These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 9010144

  • 1. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
    Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E.
    N Engl J Med; 1997 Feb 06; 336(6):393-8. PubMed ID: 9010144
    [Abstract] [Full Text] [Related]

  • 2. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.
    Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H.
    N Engl J Med; 1995 Jun 22; 332(25):1661-5. PubMed ID: 7760866
    [Abstract] [Full Text] [Related]

  • 3. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
    Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W, Warfarin Optimal Duration Italian Trial Investigators.
    N Engl J Med; 2001 Jul 19; 345(3):165-9. PubMed ID: 11463010
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
    Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ, PREVENT Investigators.
    N Engl J Med; 2003 Apr 10; 348(15):1425-34. PubMed ID: 12601075
    [Abstract] [Full Text] [Related]

  • 7. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
    Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G.
    N Engl J Med; 1998 Feb 12; 338(7):409-15. PubMed ID: 9459643
    [Abstract] [Full Text] [Related]

  • 8. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.
    Schulman S, Lindmarker P.
    N Engl J Med; 2000 Jun 29; 342(26):1953-8. PubMed ID: 10874063
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.
    Wells PS, Forgie MA, Simms M, Greene A, Touchie D, Lewis G, Anderson J, Rodger MA.
    Arch Intern Med; 2003 Apr 28; 163(8):917-20. PubMed ID: 12719200
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV, CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.
    N Engl J Med; 2001 Mar 01; 344(9):626-31. PubMed ID: 11228276
    [Abstract] [Full Text] [Related]

  • 14. Extended prophylaxis of venous thromboembolism with idraparinux.
    van Gogh InvestigatorsAcademic Medical Center, Department of Vascular Medicine, F4-211, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. h.r.buller@amc.uva.nl, Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE.
    N Engl J Med; 2007 Sep 13; 357(11):1105-12. PubMed ID: 17855671
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term management of patients after venous thromboembolism.
    Kearon C.
    Circulation; 2004 Aug 31; 110(9 Suppl 1):I10-8. PubMed ID: 15339876
    [Abstract] [Full Text] [Related]

  • 18. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P, Behounek J, Skoták M, Nevsímal L.
    Acta Chir Orthop Traumatol Cech; 2004 Aug 31; 71(4):237-44. PubMed ID: 15456102
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
    Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D.
    N Engl J Med; 1993 Nov 04; 329(19):1370-6. PubMed ID: 8413432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.